NCT02071992: Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma |
|
|
| Not yet recruiting | 1 | 24 | US | Tremelimumab, CP-675,206, Ticilimumab, MEDI3617, MEDI-3617 | F. Stephen Hodi, MD, MedImmune LLC | Metastatic Melanoma | 06/17 | 02/19 | | |
NCT02141542: Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma |
|
|
| Completed | 1 | 15 | US | Tremelimumab, CP-675,206, Ticilimumab, MEDI3617, MEDI-3617 | F. Stephen Hodi, MD, MedImmune LLC | Metastatic Melanoma | 09/20 | 09/20 | | |
